|
Drug
type |
Polymer
type |
Patients
number |
Follow-up
(month) |
Death
(%) |
MI
(%) |
ST
(%) |
TLR
(%) |
Late loss
(mm) |
ISAR-TEST 71 |
Sirolimus |
Free |
225 |
9 / 6-8* |
0.9 |
N/A |
0 |
9.3 |
0.48 |
ISAR-TEST
2 75,76 |
Sirolimus Probucol |
Free |
333 |
12 / 6-8* |
2.4 |
4.2 |
0.9 |
6.8+ |
0.23 |
|
|
|
|
24 |
4.2 |
4.5 |
0.9 |
7.7+ |
0.30 |
ISAR-TEST- 353,54 |
Sirolimus |
Free |
201 |
12 / 6-8* |
2.0 |
2.5 |
1.0 |
12.9 |
0.30 |
|
|
|
|
24 |
4.0 |
3.5 |
1.0 |
13.4 |
….. |
ISAR-TEST - 577 |
Sirolimus Probucol |
Free |
2002 |
12/6-8* |
3.6 |
3.9 |
1.1 |
10.3 |
0.31 |
LIPSIA Yukon78 |
Sirolimus |
Free |
118# |
9 |
5.1 |
3.4 |
0 |
10.2 |
0.63 |
ELUTES 79 |
Paclitaxel
0.2 a |
Free |
37 |
12 / 6* |
0 |
0 |
0 |
5.4 |
0.71 |
|
Paclitaxel
0.7 a |
Free |
39 |
12 / 6* |
0 |
2.6 |
0 |
5.1 |
0.47 |
|
Paclitaxel
1.4 a |
Free |
39 |
12 / 6* |
0 |
0 |
0 |
10.3 |
0.47 |
|
Paclitaxel
2.7 a |
Free |
37 |
12 / 6* |
2.7 |
2.7 |
2.7 |
5.4 |
0.11 |
MI: Myocardial Infarction; ST: Definite or probable stent thrombosis defined in Academic Research Consortium; TLR: Target Lesion Revascularization; *Clinical/angiographic
follow-up; + Per lesion analysis; #Patients with diabetes mellitus only; a Paclitaxel dose density, μg/mm2. |